术前使用GLP-1受体激动剂与全髋关节置换术后并发症降低相关:与减重手术比较
本研究基于全国数据库,比较肥胖(BMI>35)患者在全髋关节置换术(THA)前1年内接受减重手术、GLP-1受体激动剂(GLP-1 RA)处方或无干预的并发症差异。经倾向评分匹配后,减重手术组5年假体周围感染、脱位和翻修风险显著高于GLP-1 RA组;GLP-1 RA组与无干预组各时间点及BMI亚组 outcomes 均无显著差异。
要点
- 肥胖患者THA前减重手术与5年PJI、脱位和翻修风险增加相关
- GLP-1 RA组并发症风险与无减重干预组相当
- GLP-1 RA可能优于减重手术作为THA术前体重管理策略
核心结论
- 术前使用GLP-1 RA与减重手术相比,THA术后并发症风险更低,且安全性与无减重干预相当。
研究设计与样本
- 回顾性队列研究,查询全国数据库纳入BMI>35行初次THA的肥胖患者。
- 按术前1年内干预分为减重手术、GLP-1 RA处方和无干预三组,并行倾向评分匹配。
- 匹配后BMI>35队列每组n=2,119,另对BMI 35-40和BMI>40进行亚组分析。
主要发现
- 匹配BMI>35队列中,减重手术组5年PJI风险高于GLP-1 RA组(OR 2.20,95%CI 1.62-3.00)。
- 减重手术组5年脱位风险高于GLP-1 RA组(OR 2.03,95%CI 1.31-3.14)。
- 减重手术组5年翻修风险高于GLP-1 RA组(OR 2.75,95%CI 1.79-4.24)。
- 与无干预组相比,减重手术与PJI风险增加(OR 1.88)和翻修风险增加(OR 1.71)相关。
- GLP-1 RA组与无干预组在所有时间点和BMI亚组中 outcomes 均无显著差异。
临床怎么用
- 对于肥胖拟行THA患者,术前体重管理可优先考虑GLP-1 RA而非减重手术。
- 需结合患者具体情况个体化选择体重管理策略,并关注长期假体相关并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a risk factor for adverse outcomes following total hip arthroplasty (THA). While weight loss strategies exist, the comparative impact of these approaches on surgical outcomes remains underexplored. This study aimed to compare complications among patients who had bariatric surgery versus prescription weight loss medications before THA. METHODS: A national database was queried to identify patients who have obesity (body mass index [BMI] > 35) undergoing primary THA. Patients were stratified into three cohorts based on interventions within 1 year before THA: (1) bariatric surgery, (2) glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription, and (3) no intervention. Propensity score matching was performed to balance baseline characteristics. In addition to the cohort analysis (BMI > 35), subgroup analyses were performed for patients who had a BMI of 35 to 40 and BMI > 40. Primary outcomes were periprosthetic joint infection (PJI), dislocation, aseptic loosening, and revision surgery at 90 days, two years, and five years. RESULTS: In the matched BMI greater than 35 cohort (n = 2,119 per group), patients who had prior bariatric surgery had higher odds of PJI (odds ratio [OR] 2.20, 95% confidence interval [CI] 1.62 to 3.00), dislocation (OR 2.03, 95% CI 1.31 to 3.14), and revision surgery (OR 2.75, 95% CI 1.79 to 4.24) at five years compared to the GLP-1 RA cohort. Compared to the no-intervention cohort, bariatric surgery was associated with increased PJI (OR 1.88) and revision (OR 1.71) risks. The GLP-1 RA cohort showed no significant differences in outcomes compared to the no intervention cohort across all time points and BMI subgroups. CONCLUSIONS: Preoperative GLP-1 RA use is associated with lower complication risks compared to bariatric surgery and demonstrates a safety profile comparable to no weight loss intervention. These findings highlight potential influences of weight loss management strategies on longer term THA outcomes.
引用
- Bcharah G, Wininger AE, Tarabichi S, et al. Preoperative Glucagon-Like Peptide-1 Agonist Use Is Associated With Decreased Complications Compared to Bariatric Surgery Following Primary Total Hip Arthroplasty. J Arthroplasty. 2026. PMID: 42001909. doi:10.1016/j.arth.2026.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。